Document Detail

Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer.
MedLine Citation:
PMID:  23199207     Owner:  NLM     Status:  MEDLINE    
AIM: This work aimed to determine if the treatment outcomes of bladder cancer could be improved by targeting micelles that are decorated with bladder cancer-specific ligands on the surface and loaded with the chemotherapeutic drug paclitaxel.
MATERIALS & METHODS: Targeting efficacy and specificity was determined with cell lines. An in vivo targeting and anti-tumor efficacy study was conducted in mice carrying patient-derived xenografts.
RESULTS & DISCUSSION: Targeting micelles were more efficient than nontargeting micelles in delivering the drug load into bladder cancer cells both in vitro and in vivo (p < 0.05). The micelle formulation of paclitaxel was less toxic than free paclitaxel in Cremophor(®) (Sigma, MO, USA) and allowed administration of three-times the maximum tolerated dose without increasing the toxicity. Targeting micelles were more effective than the nontargeting micelles in controlling cancer growth (p = 0.0002) and prolonging overall survival (p = 0.002).
CONCLUSION: Targeting micelles loaded with paclitaxel offer strong potential for clinical applications in treating bladder cancer.
Tzu-Yin Lin; Yuan-Pei Li; Hongyong Zhang; Juntao Luo; Neal Goodwin; Tingjuan Gao; Ralph de Vere White; Kit S Lam; Chong-Xian Pan
Related Documents :
23780887 - Inhibition of protein phosphatase 2a radiosensitizes pancreatic cancers by modulating c...
23585057 - Primary anti-proliferative activity evaluation of 1-(quinolizidin-1'-yl)methyl- and 1-(...
24140887 - Luteolin attenuates tgf-β1-induced epithelial-mesenchymal transition of lung cancer ce...
24348907 - Itraq-based proteomic analysis of polyploid giant cancer cells and budding progeny cell...
15297527 - Comparison of real-time pcr signal-amplified in situ hybridization and conventional pcr...
20410067 - Do geodemographic typologies explain variations in uptake in colorectal cancer screenin...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2012-12-02
Journal Detail:
Title:  Nanomedicine (London, England)     Volume:  8     ISSN:  1748-6963     ISO Abbreviation:  Nanomedicine (Lond)     Publication Date:  2013 Aug 
Date Detail:
Created Date:  2013-08-06     Completed Date:  2014-05-06     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  101278111     Medline TA:  Nanomedicine (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  1239-51     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line, Tumor
Cell Proliferation / drug effects
Drug Delivery Systems / adverse effects*
Maximum Tolerated Dose
Paclitaxel / administration & dosage*,  chemistry
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*,  pathology
Grant Support
Reg. No./Substance:
0/Micelles; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacogenomics of chemotherapeutic susceptibility and toxicity.
Next Document:  Exocrine pancreatic insufficiency following esophagectomy.